4 results match your criteria: "Centre for Strategic Planning and Management of Biomedical Health Risks Management[Affiliation]"
Genetic Predictors of Antipsychotic Efflux Impairment via Blood-Brain Barrier: Role of Transport Proteins.
Genes (Basel)
May 2023
Centre for Strategic Planning and Management of Biomedical Health Risks Management, Moscow 119121, Russia.
Article Synopsis
- Antipsychotic medications can cause adverse drug reactions (ADRs), which remain a significant issue in psychiatry despite advancements in new APs.
- Research has identified genetic factors that influence drug transport across the blood-brain barrier, particularly focusing on specific transporter proteins like P-gp, BCRP, and MRP1 in patients with schizophrenia.
- The authors propose a pharmacogenetic test called PTAP-PGx to assess genetic variations affecting drug transport, along with a risk assessment tool and decision-making guidelines to help psychiatrists better manage these ADRs.
Genetic Biomarkers of Antipsychotic-Induced Prolongation of the QT Interval in Patients with Schizophrenia.
Int J Mol Sci
December 2022
Institute of Personalized Psychiatry and Neurology, V. M. Bekhterev National Medical Research Centre for Psychiatry and Neurology, 192019 Saint Petersburg, Russia.
Antipsychotics (AP) induced prolongation of the QT interval in patients with schizophrenia (Sch) is an actual interdisciplinary problem as it increases the risk of sudden death syndrome. Long QT syndrome (LQTS) as a cardiac adverse drug reaction is a multifactorial symptomatic disorder, the development of which is influenced by modifying factors (APs' dose, duration of APs therapy, APs polytherapy, and monotherapy, etc.) and non-modifying factors (genetic predisposition, gender, age, etc.
View Article and Find Full Text PDFThe Role of D-Serine and D-Aspartate in the Pathogenesis and Therapy of Treatment-Resistant Schizophrenia.
Nutrients
December 2022
Institute of Personalized Psychiatry and Neurology, Shared Core Facilities, V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology, 192019 Saint Petersburg, Russia.
Schizophrenia (Sch) is a severe and widespread mental disorder. Antipsychotics (APs) of the first and new generations as the first-line treatment of Sch are not effective in about a third of cases and are also unable to treat negative symptoms and cognitive deficits of schizophrenics. This explains the search for new therapeutic strategies for a disease-modifying therapy for treatment-resistant Sch (TRS).
View Article and Find Full Text PDFCytokine Imbalance as a Biomarker of Treatment-Resistant Schizophrenia.
Int J Mol Sci
September 2022
Institute of Personalized Psychiatry and Neurology, Shared Core Facilities, V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology, 192019 Saint Petersburg, Russia.
Treatment-resistant schizophrenia (TRS) is an important and unresolved problem in biological and clinical psychiatry. Approximately 30% of cases of schizophrenia (Sch) are TRS, which may be due to the fact that some patients with TRS may suffer from pathogenetically "non-dopamine" Sch, in the development of which neuroinflammation is supposed to play an important role. The purpose of this narrative review is an attempt to summarize the data characterizing the patterns of production of pro-inflammatory and anti-inflammatory cytokines during the development of therapeutic resistance to APs and their pathogenetic and prognostic significance of cytokine imbalance as TRS biomarkers.
View Article and Find Full Text PDF